Comparison of eplerenone versus melatonin as therapeutic options for the treatment of non-resolving and chronic central serous chorioretinopathy

SADDI; TOMAS NABIL; J.P. REAL; LÁVAQUE, ELEONORA B.; GRAMAJO L; JUAREZ CP; ROSENSTEIN R; LUNA J.D

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Lugar: Rockville, MD 20852; Año: 2019 vol. 60

0146-0404

urpose : At present, there are no optimal therapies for chronic CSCR (central serous chorioretinopathy). Eplerenone and melatonin are two of the many therapeutic option described for this systemic disease. The aim of this study is to compare the efficacy of melatonin and eplerenone for CSCR treatment.Methods : A comparative, retrospective study was developed with 36 patients with chronic CSCR. Twenty patients were treated with 50 mg/day of oral eplerenone for 3 months and 16 patients were treated orally with 3 mg melatonin three times a day for 1 month. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS best-corrected visual acuity (BCVA), complete ophthalmic examination and Optical Coherence Tomography. Four time points were used: baseline, 1, 3 and 6 months.Results : At one month follow up, CMT (central macular thickness) showed a significant decrease (p< 0.005) on both treatment groups, but change in macular thickness wa